Drug License Renewal: Deadlines, Documents & Process
Quick Answer
Drug licences in India are no longer "renewed" — they are retained. Since a 2017 amendment to the Drugs and Cosmetics Rules, 1945, a valid drug licence remains valid perpetually, provided the licensee pays a licence retention fee every five years from the date the licence was issued.
Miss that deadline and a six-month window applies, during which a late fee of 2% of the licence fee per month (or part of a month) accrues. If the retention fee and late fee are still unpaid at the end of those six months, the licence is deemed to have been cancelled — and continuing to operate at that point is an offence under the Drugs and Cosmetics Act, 1940.
Why "Renewal" Is the Wrong Word Now
Before 2017, drug licences carried a fixed five-year validity, and expiry meant submitting a fresh application — repeating much of the original licensing exercise, documents and all.
That changed with G.S.R. 1337(E), notified on 27 October 2017 as the Drugs and Cosmetics (Tenth Amendment) Rules, 2017. The amended rules state plainly that a licence, "unless sooner suspended or cancelled, shall remain valid perpetually." The same notification omitted the words "or renewal" from Rule 65, removing the term from the sale-licence provisions altogether.
Compliance is no longer confirmed through a repeated approval cycle. Instead, adherence to the licence conditions is assessed by inspection "not less than once in three years or as needed as per risk based approach" — periodic verification rather than periodic reapplication.
In practice, most pharmacy owners — and plenty of official-sounding guides — still say "renewal" out of habit. The statutory term, and the one that governs your actual deadline, is retention.
Which rule applies to your licence
For sale licences — the ones retail and wholesale pharmacies hold — the operative provision is Rule 63 of the Drugs and Cosmetics Rules, 1945. It names Forms 20, 20A, 20B, 20BB, 20F, 20G, 21, 21A, 21B and 21BB. Manufacturing and cosmetics licences sit in parallel rules — not Rule 69, which only deals with fees: Rule 72 covers Forms 25, 25B and 25F, Rule 73AA the Form 25A loan licence, and Rule 140 the cosmetics Forms 32, 32A and 33. The five-year cycle, the 2% monthly late fee and the six-month limit read the same across all of them.
The Five-Year Retention Cycle and Deadline
Rule 63(1) ties the deadline to your own licence: the fee falls due before the expiry of every succeeding period of five years from the date the licence was issued. Not the calendar year, and not five years from your last payment unless that payment happened to land exactly on the five-year mark.
Rule 63(2) sets the amount: the retention fee is equivalent to the fee required for the grant of that licence, with no deduction. Manufacturing licences under Rule 72 — and the Form 25A loan licence under Rule 73AA — use the same formula but exclude the inspection fee paid for grant of the licence. That carve-out does not exist in Rule 63(2), so a sale licence pays the full grant fee over again.
Because the deadline is keyed to your licence's issue date, the usual way pharmacies get caught out isn't ignorance of the retention system. It's losing track of which five-year block they are currently in — especially for older licences granted well before state portals made status lookups straightforward.
What Happens If You Miss the Deadline
The structure here is consistent nationally, because it sits in the central rules rather than in state practice:
- A six-month window opens: The licence does not lapse the moment the deadline passes. Rule 63(3) allows payment to be made late, for up to six months.
- A 2% monthly late fee accrues: Calculated at 2% of the licence fee "for every month or part thereof" — so a delay of one day into a new month costs the same as a full month.
- After six months, the licence is deemed cancelled: This is the part most summaries get wrong. The rule does not say suspended. It says that in the event of non-payment, "the licence shall be deemed to have been cancelled" — no order, no notice, no further step required.
- Operating on a cancelled licence is an offence: Running a pharmacy, wholesale outlet or manufacturing unit without a valid licence falls under the penalty provisions of the Drugs and Cosmetics Act, 1940. A Drug Inspector can seal premises, seize stock and initiate prosecution.
- Getting back in business means starting over: Because the licence is cancelled rather than dormant, restoring operations generally means a fresh licence application and a fresh inspection — not a late payment.
Cancelled, not suspended — and the difference is the whole point
A suspended licence is one an authority has stopped, and can restore. A deemed cancellation happens automatically, by operation of Rule 63(3), with nothing left to restore. That is precisely why a lapsed retention can't be fixed by paying the overdue amount afterwards: there is no longer a licence for the payment to attach to. Any guide telling you the licence is merely "suspended" after six months is describing a milder outcome than the rule actually provides for.
A worked example makes the arithmetic concrete. Take a pharmacy holding both Form 20 and Form 21, in a state where each carries a grant fee of ₹1,500 — so ₹3,000 in base retention fees. Pay three months late and the penalty is 6% (2% × 3 months) on that base: about ₹180. Pay a day into the seventh month and there is nothing to pay, because the licence is already gone. The cost curve isn't gradual; it falls off a cliff at six months.
Licence fees are set by each state's fee schedule and revised periodically. ₹1,500 per form is a common figure but not a national rate — confirm the current amount with your State Drug Licensing Authority before budgeting from it.
What the Jan Vishwas Acts of 2023 and 2026 Changed
A separate reform matters here, and it has arrived in two waves. The Jan Vishwas (Amendment of Provisions) Act, 2023, which received Presidential assent on 11 August 2023, amended 183 provisions across 42 central laws — the Drugs and Cosmetics Act, 1940 among them — moving many technical, non-safety-critical offences away from mandatory imprisonment and toward monetary penalties. Its Drugs and Cosmetics Act amendments were notified into force from 31 December 2024.
The second wave went further. The Jan Vishwas (Amendment of Provisions) Act, 2026 received Presidential assent on 7 April 2026 and amends 79 central Acts across 784 provisions. For the Drugs and Cosmetics Act it omits Section 29 outright, omits sub-sections (1A) and (2) of Section 30, converts the cosmetics offence under Section 27A(ii) into a civil penalty of ₹1,00,000 or three times the value of the cosmetics confiscated, raises Section 28A to a penalty of ₹3–5 lakh, and inserts a new Section 30A creating an adjudication route — an adjudicating officer, a show-cause notice, a hearing, and a thirty-day appeal — for penalties that previously went to court.
| Provision | Before Jan Vishwas | Position after the 2023 and 2026 Acts |
|---|---|---|
| Section 27(d) — misbranded or Not-of-Standard-Quality drugs, excluding those causing serious harm | Imprisonment up to 2 years and fine, with ₹20,000 as the statutory minimum | Made compoundable under Section 32B by the 2023 Act, and left untouched by the 2026 Act |
| Section 29 — misuse of a Government Analyst's report in advertising | Punishable with fine up to ₹5,000 | Raised in 2023 to a penalty up to ₹1,00,000; the section is omitted altogether by the 2026 Act |
| Section 30(2) — repeat offence under Section 29 | Imprisonment up to 2 years, or a fine of not less than ₹10,000, or both | Imprisonment removed in 2023, replaced by a fine of not less than ₹5 lakh; sub-sections (1A) and (2) then omitted by the 2026 Act |
| Section 32B — compounding of offences | Available for a narrower set of offences | Widened in 2023 to Sections 27(d) and 27A(ii); narrowed by the 2026 Act so that 27A(ii) and 28A drop out and 27(d) remains |
| Section 30A — adjudication of penalties | No adjudication route; penalties ran through the courts | Inserted by the 2026 Act: an adjudicating officer, show-cause and hearing, a thirty-day appeal, and recovery as an arrear of land revenue |
Two things are worth reading carefully. First, neither reform touches genuinely dangerous violations — adulterated or spurious drugs causing serious harm remain subject to the Act's harshest provisions, including lengthy imprisonment. Second, imprisonment risk fell for technical lapses, but the financial exposure rose sharply in exchange, in some cases by a factor of twenty. Both Acts also build in an automatic revision: fines and penalties rise by 10% of the minimum amount prescribed, after the expiry of every three years from commencement. The 2023 Act's Drugs and Cosmetics Act amendments commenced on 31 December 2024, which puts that first revision at 31 December 2027.
The practical takeaway: a missed retention deadline or a documentation lapse is less likely to end in criminal prosecution than it once was, and considerably more expensive if it escalates. Staying ahead of the deadline is now a financial priority as much as a legal one.
The 2026 Act received Presidential assent on 7 April 2026 and was published in the Gazette on 8 April 2026, but it comes into force on a date the Central Government appoints by notification, and different dates may be appointed for different enactments. Until that notification issues for the Drugs and Cosmetics Act, the 2023 position remains the law in force.
Documents Typically Required for Retention
Exact checklists vary by state portal, but most retention applications ask for:
- Identity and constitution proof: PAN and Aadhaar of the proprietor, partners or directors, plus the incorporation certificate, partnership deed or LLP agreement as applicable.
- Premises and tenancy verification: A current registered rent or lease agreement, or the sale deed, together with a recent utility bill or tax receipt confirming the address.
- Site and layout plan: Matching the space actually in use — 10 sq. m minimum for retail, 15 sq. m where wholesale or composite operations are carried on from the same premises.
- Cold storage proof: Refrigerator purchase invoice and a declaration that it remains operational, for licences covering Schedule C and C(1) drugs.
- Personnel documentation: The Registered Pharmacist's current registration certificate, appointment letter and consent for a retail licence, or the Competent Person's qualification and experience proof for wholesale.
- A compliance declaration: A self-declaration or affidavit confirming adherence to the Drugs and Cosmetics Act and Rules through the preceding licence block.
The Retention Process, Step by Step
- 1
Log in to your state's drug licensing portal
Use your existing licence number and firm ID. Many states run the Gujarat-originated XLN (Xtended Licensing Node) platform; others use their own — Madhya Pradesh, for example, runs an Online Drugs Licensing System through MPOnline. Confirm which system applies to you before you start.
- 2
Verify the auto-populated legacy data
Premises address, firm constitution and the pharmacist or competent person on record must match your current reality. A mismatch needs a separate amendment application first — it cannot be corrected inside the retention flow.
- 3
Upload the supporting documents
Usually as PDFs within a per-file size limit. Scans that exceed the limit are the single most common reason a submission stalls before it is even reviewed.
- 4
Pay the retention fee
Through the portal's payment gateway. Keep the generated e-Challan or receipt — it is your proof that payment was made inside the five-year window, which is the fact that matters if the date is ever questioned.
- 5
Await departmental review
The licensing authority conducts a desk review and may assign a Drug Inspector for physical verification, consistent with the risk-based inspection cycle that replaced the old renewal approval.
- 6
Respond promptly to any query or show-cause notice
An unresolved query can hold up the retention approval even after the fee is paid.
- 7
Download the retention certificate
Once approved, display it alongside the original licence at the premises.
Common Mistakes Pharmacies Make With Retention
- Confusing "no expiry" with "no deadline": The licence doesn't expire. The retention fee attached to it has a hard deadline every five years, and missing it by more than six months cancels the licence outright.
- Treating the grace period as the plan: Paying inside the six-month window is legal but avoidable — it converts a routine fee into one carrying a 2%-per-month penalty, for no benefit.
- Letting pharmacist registration lapse separately: The drug licence and the pharmacist's registration are maintained under different laws, by different authorities, on different clocks. A lapsed registration can hold up a retention approval even when the fee is paid on time.
- Submitting outdated premises or personnel details: Legacy data that no longer matches the shop triggers avoidable queries during departmental review — and those queries are what turn a two-week approval into a two-month one.
- Assuming the process is identical everywhere: The national rules — the five-year cycle, the late fee, the deemed cancellation — are uniform. The portal, document formats and processing timelines are not.
Rule references, fees and penalty figures are set by the Drugs and Cosmetics Rules, 1945 and amended over time, including by the Jan Vishwas (Amendment of Provisions) Acts of 2023 and 2026. State authorities also differ in process. This is general information, not legal advice — confirm current requirements with your State Drug Licensing Authority.
Frequently Asked Questions
Do drug licences in India still expire after five years?
No, not since 2017. Under G.S.R. 1337(E), a valid licence remains valid perpetually unless suspended or cancelled. What recurs every five years is a mandatory licence retention fee, not a full reapplication.
What is the difference between drug licence "renewal" and "retention"?
They are used interchangeably in conversation, but retention is the correct current term. Renewal meant reapplying for a fixed-term licence; retention means paying a fee to maintain a licence that is already perpetual. The word "renewal" was omitted from Rule 65 by the 2017 amendment.
What happens if I miss the drug licence retention deadline?
A six-month window applies, with a late fee of 2% of the licence fee for every month or part of a month. If the retention fee and late fee are still unpaid at the end of that window, Rule 63(3) provides that the licence shall be deemed to have been cancelled — and operating without a valid licence is an offence under the Drugs and Cosmetics Act, 1940.
Is the licence suspended or cancelled if the retention fee is never paid?
Cancelled. The rule says the licence "shall be deemed to have been cancelled" — it happens automatically, without an order from the licensing authority. This is stronger than suspension, and it is why a lapse generally cannot be cured by paying the overdue amount later.
Do I need to reapply from scratch if my licence retention lapses completely?
Typically yes. Once the six-month window passes without payment and the licence is deemed cancelled, resuming operations generally requires a fresh licence application and a new inspection rather than a catch-up payment.
How much is the drug licence retention fee?
Rule 63(2) sets it as equivalent to the fee required for the grant of that licence, so it matches your original licence fee for that category. Manufacturing licences under Rule 72 use the same formula excluding the inspection fee paid for grant of the licence — Rule 63(2) has no such carve-out. The underlying fee amounts are set by each state, so confirm the current figure with your State Drug Licensing Authority.
Has the penalty for drug licence violations become more lenient?
Not for dangerous violations — adulterated or spurious drugs causing harm still carry the Act's severest penalties. For technical violations under Section 27(d), the Jan Vishwas Act, 2023 removed mandatory imprisonment and made the offence compoundable, while substantially increasing the monetary penalties in exchange; an automatic revision of 10% of the minimum amount falls due from 31 December 2027. The Jan Vishwas Act, 2026 goes further — it omits Section 29, converts several cosmetics and record-keeping offences into civil penalties, and routes them through a new Section 30A adjudication process. It received assent on 7 April 2026 and takes effect on notification.
Is the drug licence retention process the same in every state?
The core national rules are — the five-year cycle, perpetual validity, the 2% monthly late fee and deemed cancellation after six months all sit in the central Drugs and Cosmetics Rules, 1945. The online portal, document upload requirements and processing timelines vary by state.
Conclusion
The 2017 shift from fixed-term renewal to perpetual licensing with periodic retention genuinely reduced the paperwork burden on Indian pharmacies. What it also did was move the risk: from "forgetting a full reapplication" — visible, dated, hard to miss — to "missing a quiet five-year fee deadline" that no one sends you a reminder for. Add the Jan Vishwas Act's trade of lighter criminal exposure for heavier financial penalties, and the conclusion is the same from either direction. Track your licence's specific five-year cycle, keep documentation and personnel records current, and never let a routine fee payment run past the six-month cliff.
For the broader licensing picture, see Types of Drug Licenses in India: Retail vs Wholesale vs Composite, or start from the full overview in the complete pharmacy drug licensing and compliance guide.
Retention deadlines sit alongside the rest of the compliance calendar — Schedule H1 recordkeeping, the narcotic drug register where controlled substances are stocked, and the inspection readiness that all of it feeds into.
Keep the payment receipts with the rest of your inspection file: our compliance checklist covers retention-fee receipts and the rest of the file an inspector can ask for, along with how long each record has to be kept.
Don't let a five-year deadline arrive unannounced
BitMed's Pharmacy Management Software keeps billing, inventory and compliance recordkeeping in one place, so licensing deadlines don't get lost in day-to-day operations.
Explore BitMed